SITE014-0125

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-07-23

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 62); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 75); relationship: not assessed

severe serious assessed

Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-20 (study day 77); relationship: Y; serious criteria: life-threatening

severe serious assessed

Grade 4 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 122); relationship: not assessed; serious criteria: life-threatening

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 202); relationship: N

Data queries

No data queries.